Clinical Trial

Trial Protocol ID 1403-0011_Brightline 2 *RIT*

Trial Description

Brightline 2 – A Phase II/III, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type solid tumours-biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsor

  • Boehringer Ingelheim

ClinicalTrials.gov NCT ID

  • NCT05512377